BE substrate: CROs, volunteers, units, contracts, conduct.
The operational architecture beneath every BE study. CRO oversight model · healthy-volunteer regimes (registries, screening, washouts) · clinical-pharmacology unit infrastructure · sponsor-CRO contracting · the five-phase study conduct sequence · the bioanalytical bridge. The substrate iFeed runs on.
CRO oversight model.
5 contracting patternsThe BE CRO is not a single homogeneous category. The contracting pattern determines who owns the protocol, who owns the audit trail, who is liable when ANVISA inspects, who answers a 483 observation. Five patterns dominate the 2026 market — each with distinct sponsor exposure, distinct cost, distinct time-to-readiness.
Full-service CRO.
End-to-end: protocol, ethics filing, recruitment, dosing, sampling, bioanalysis, statistics, CSR. Sponsor signs off; CRO owns conduct. Default for first-time generic sponsors. Higher cost; lower sponsor operational load.
Functional service · FSP.
Sponsor retains protocol authorship and CSR; CRO provides conduct phases (clinical conduct, bioanalysis). Common for repeat-generic sponsors with internal regulatory teams.
Split-CRO · clinical / bioanalytical.
Clinical conduct (CPU dosing) at one CRO; bioanalysis at another. Common for sponsors leveraging specialised LC-MS/MS labs. Cross-CRO data integration risk.
Captive CPU.
Sponsor-owned clinical-pharmacology unit. Increasingly rare; used by largest generics (Sun Pharma, Cipla) for India-domestic studies. Highest control, highest fixed-cost overhead.
Hybrid · academic-CPU.
University clinical pharmacology unit conducts the dosing and sampling; commercial CRO handles bioanalysis. Common for biosimilar bridging studies and rare-disease BE.
Healthy-volunteer regimes.
Registries, screening, washoutsThe healthy volunteer is the unit of work for a BE study. Brazil-specific implementation sources appear to make volunteer control a distinct operational layer; exact registry, washout, and enrolment constraints should be verified against current ANVISA text before study use. The complete landscape:
Clinical-pharmacology unit infrastructure.
5 componentsThe CPU is where the BE study actually happens — the place a healthy volunteer arrives at 06:00, gets dosed at 08:00, and stays through 24/48/72 hours of sampling. Five infrastructure components. Each one a regulator inspection target. Each one a cause of failure if absent.
Screening rooms.
Vital signs, ECG, blood draw for safety labs. 7-day screening window typical; pregnancy testing day-of for women of child-bearing potential.
Dosing bay.
Witnessed administration. IMP storage at room temp / 2-8 °C. Mouth check post-dosing. Drinking water restrictions for ±1h around dose.
Sampling bay.
Indwelling cannula. Pre-dose + 18-22 timepoint sampling. Plasma separation within 30 min of collection. Storage at -70 to -80 °C.
Crossover housing.
Period 1 confinement 24-48h. Washout-window release. Period 2 readmission. Same volunteer, same beds, same meals.
Pharmacy & archive.
IMP receipt, accountability ledger, randomisation envelopes. Source data archive (paper + EDC). 15-year retention typical post-marketing authorisation.
Sponsor-CRO contracting patterns.
8 frame contractsThe contract is the legal substrate. Once a 483 observation lands or a deficiency letter arrives, the contract determines who pays for the rerun. Eight contract types cover almost all BE work in 2026.
Fixed-price study contract.
Single deliverable. CSR + audit-ready dossier. Most common for first-time generics. Risk on CRO for cost overruns.
Time-and-materials.
Hourly + reagent costs. Used for novel formulations or unknown screening yield. Risk on sponsor.
Per-volunteer.
Common in India CROs. Per-volunteer fee covers screening + dosing + sampling. Bioanalysis costed separately.
Master service agreement.
MSA + Work Orders. Used by repeat-generic sponsors filing many ANDAs / generic registrations annually.
Risk-share rerun.
If first-pass BE fails, CRO covers rerun cost. Higher initial fee. Used by sponsors with tight ANDA timelines.
Pass-through bioanalysis.
CRO subcontracts to specialist BMV lab. Sponsor signs three-way contract; data flows back to CRO for CSR integration.
Inspection indemnity.
Specific clause for regulator inspection findings and data-reliability follow-up. Exact allocation of cost, rerun responsibility, and sponsor access should be contractually explicit.
Data ownership clause.
Raw data, audit trail, source-data ownership. Sponsor typically retains; CRO keeps copy under regulator-defined retention.
Study conduct phases.
5-phase sequenceThe five phases are sequential, with regulator-specified handoffs. Skipping a phase, or running phases out of order, creates inspection-readiness risk during BE conduct, particularly around washout and crossover transitions.
Run-in.
7-day screening window. Vital signs, ECG, lab safety screen. Pregnancy test day-of-dose. Confirm no concurrent meds, no recent BE participation. Eligibility lock at -1 day.
Dosing.
Period 1. Randomisation envelope opened. Witnessed dose at T=0. Pre-dose blood sample. Post-dose timepoints per protocol (typical 18-22 timepoints over 24-72h).
Sampling.
Plasma collection per timepoint. K2-EDTA tubes typical. Centrifuge within 30 min. Aliquot to 2 cryotubes (primary + backup). Storage -70 to -80 °C.
Washout.
Inter-period gap. ≥7 half-lives recommended (covers >99% drug clearance). Volunteer released; readmits at end of washout. Concurrent BE participation prohibited.
Crossover.
Period 2. Same protocol as Period 1 with crossover treatment per randomisation. Same sampling timepoints. Same safety monitoring. Subject completion at last sample + safety follow-up.
The bioanalytical bridge.
Where BE meets BMVThe BE study and the bioanalytical method are tightly coupled. BE plasma samples should be analysed with a validated method before PK/statistical conclusions are drawn. The handoff between clinical conduct and bioanalysis is a recurring inspection-readiness point.
BE conduct → BMV analysis → statistics.
Validated method consumes BE plasma samples. Calibration curve, QCs, ISR expectations, failed-batch rules, and reanalysis authority should be pre-defined in the applicable protocol/SOP stack and aligned with current guidance.
Data integration: clinical ↔ bioanalytical.
EDC, LIMS, statisticsThe BE substrate ends in three parallel data streams that should reconcile before submission: clinical EDC, bioanalytical LIMS, and statistical SAP output. Reconciliation is where source-data traceability becomes load-bearing for dossier review and inspection readiness.
Clinical EDC.
Medidata Rave · Veeva Vault EDC · Oracle Inform. Concomitant meds, AE, vitals, dosing log, randomisation. Source-data verification per CRA visit. Audit-trail per 21 CFR 11.
Bioanalytical LIMS.
Watson LIMS · SCIEX OS · Waters MassLynx + iSubmit. Sample inventory, calibration curves, QC results, raw data archive. Part 11-compliant audit trail.
Statistical analysis.
SAS 9.4 · Phoenix WinNonlin · R + ncar / nlmixr. PK parameter calculation (Cmax, AUC0-t, AUC0-inf). Log-transform + TOST. SAP-locked outputs.
Official source register.
Regulator / ICH anchorsICH M13A bioequivalence guideline.
Official FDA-hosted page for ICH M13A on bioequivalence for immediate-release solid oral dosage forms. Use as the first harmonised anchor for conventional oral IR BE framing.
BCS-based biowaiver guidance.
Official ICH M9 Step 4 guideline. Use for BCS classification, solubility/permeability thinking, and eligible biowaiver conditions.
Bioanalytical method validation and study sample analysis.
Official ICH M10 Step 4 guideline. Use for the bioanalytical evidence layer that supports BA/BE concentration data.
Product-specific guidances for generic development.
FDA product-specific guidance collection. Use before protocol lock because product-level recommendations can change design, fed/fasted, analyte, and BE expectations.
US bioavailability and bioequivalence regulation.
Electronic Code of Federal Regulations anchor for US BA/BE definitions and requirements. Use for statutory/regulatory context, not as a complete study-design manual.
Guideline on the investigation of bioequivalence.
EMA scientific guideline landing page for BE investigation. Use for EU framing, while checking product-specific or updated procedural context where relevant.
Multisource generic products and interchangeability.
WHO IRIS record for multisource pharmaceutical product guidance. Use as a WHO anchor for generic interchangeability and BE expectations in broader access settings.